CD6 was part of the Tc17 signature highly expressed in CD and can be targeted by monoclonal antibodies which are already in clinical use to treat patients with psoriasis, providing a possible rationale for this therapeutic option in CD patients36. Here, CD6 is linked to Cowden disease.